Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Authors

Institutions

Publication Details

Journal
Journal of Thoracic Oncology
Published
2024-10-04
DOI
https://doi.org/10.1016/j.jtho.2024.09.1439
Citations
22
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
6.22

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Tudor–Eliade Ciuleanu, Adam Płużański, Shun Lü, Hossein Borghaei et al.
22 citations
Journal of Thoracic Oncology
Cancer Immunotherapy and Biomarkers
6.22
article

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Tudor–Eliade Ciuleanu, Adam Płużański, Shun Lü, Hossein Borghaei, Bogdan Żurawski, Diederik J. Grootendorst, Julie R. Brahmer, Manuel Cobo, Michael Schenker, Vipul Devas, Kenneth J. O’Byrne, Marina Tschaika, Luis Paz‐Ares, David P. Carbone, Martin Reck, Solange Peters, Reyes Bernabé, Makoto Nishio, Suresh S. Ramalingam, Thomas John, Jong-Seok Lee, Takekazu Aoyama
article en
22 citations

Abstract

No abstract available for this paper.
Journal of Thoracic OncologyVol. 20(1)
Universidad Complutense de Madrid (ES), Fox Chase Cancer Center (US), Translational Research Institute (AU), Emory University (US), Queensland University of Technology (AU), Austin Hospital (AU), Princess Alexandra Hospital (AU), Centre Hospitalier Universitaire Vaudois (CH), Shanghai Chest Hospital (CN), Seoul National University Bundang Hospital (KR), University of Medicine and Pharmacy of Craiova (RO), Bristol-Myers Squibb (United States) (US), Institute of Oncology Prof. Dr. Ion Chiricuta (RO), Hospital Universitario 12 De Octubre (ES), Hôpital Orthopédique de la Suisse Romande (CH), German Center for Lung Research (DE), Instituto de Biomedicina de Sevilla (ES), Bristol-Myers Squibb (Sweden) (SE), LungenClinic Grosshansdorf (DE), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Sidney Kimmel Comprehensive Cancer Center (US), Instituto de Investigación Biomédica de Málaga (ES), Japanese Foundation For Cancer Research (JP), The Ohio State University (US), University of Lausanne (CH)
Bristol-Myers Squibb, Ono Pharmaceutical
Good health and well-being
Openalex Percentile: Top 3%
Cancer Immunotherapy and Biomarkers
6.22
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.